These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 19892545)

  • 1. Pharmacological significance of glycosylation in therapeutic proteins.
    Li H; d'Anjou M
    Curr Opin Biotechnol; 2009 Dec; 20(6):678-84. PubMed ID: 19892545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The sweet tooth of biopharmaceuticals: importance of recombinant protein glycosylation analysis.
    Lingg N; Zhang P; Song Z; Bardor M
    Biotechnol J; 2012 Dec; 7(12):1462-72. PubMed ID: 22829536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression systems for therapeutic glycoprotein production.
    Durocher Y; Butler M
    Curr Opin Biotechnol; 2009 Dec; 20(6):700-7. PubMed ID: 19889531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins.
    van Beers MM; Bardor M
    Biotechnol J; 2012 Dec; 7(12):1473-84. PubMed ID: 23027660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The significance of glycosylation analysis in development of biopharmaceuticals.
    Kawasaki N; Itoh S; Hashii N; Takakura D; Qin Y; Huang X; Yamaguchi T
    Biol Pharm Bull; 2009 May; 32(5):796-800. PubMed ID: 19420744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioprocess factors affecting glycoprotein oligosaccharide structure.
    Goochee CF
    Dev Biol Stand; 1992; 76():95-104. PubMed ID: 1478360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biopharmaceuticals in China.
    Hu X; Ma Q; Zhang S
    Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and development of biopharmaceuticals: current issues.
    Strohl WR; Knight DM
    Curr Opin Biotechnol; 2009 Dec; 20(6):668-72. PubMed ID: 19896824
    [No Abstract]   [Full Text] [Related]  

  • 9. Large scale production of recombinant human lactoferrin in the milk of transgenic cows.
    van Berkel PH; Welling MM; Geerts M; van Veen HA; Ravensbergen B; Salaheddine M; Pauwels EK; Pieper F; Nuijens JH; Nibbering PH
    Nat Biotechnol; 2002 May; 20(5):484-7. PubMed ID: 11981562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Getting the glycosylation right: implications for the biotechnology industry.
    Jenkins N; Parekh RB; James DC
    Nat Biotechnol; 1996 Aug; 14(8):975-81. PubMed ID: 9631034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical aspects of altered glycosylation of glycoproteins in cancer.
    Orntoft TF; Vestergaard EM
    Electrophoresis; 1999 Feb; 20(2):362-71. PubMed ID: 10197444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of Fc-mediated effector functions of monoclonal antibodies.
    Strohl WR
    Curr Opin Biotechnol; 2009 Dec; 20(6):685-91. PubMed ID: 19896358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-glycosylation is required for binding of murine pregnancy-specific glycoproteins 17 and 19 to the receptor CD9.
    Ha CT; Waterhouse R; Warren J; Zimmermann W; Dveksler GS
    Am J Reprod Immunol; 2008 Mar; 59(3):251-8. PubMed ID: 18275518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-1 cells and naturally occurring antibodies: influencing the immunogenicity of recombinant human therapeutic proteins?
    Sauerborn M; Schellekens H
    Curr Opin Biotechnol; 2009 Dec; 20(6):715-21. PubMed ID: 19892544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression--glycosylation.
    Parekh RB
    Biologicals; 1994 Jun; 22(2):113-9. PubMed ID: 7917227
    [No Abstract]   [Full Text] [Related]  

  • 16. Appropriate mammalian expression systems for biopharmaceuticals.
    Werner RG; Noé W; Kopp K; Schlüter M
    Arzneimittelforschung; 1998 Aug; 48(8):870-80. PubMed ID: 9748718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of therapeutic protein in vivo activities through glycoengineering.
    Elliott S; Lorenzini T; Asher S; Aoki K; Brankow D; Buck L; Busse L; Chang D; Fuller J; Grant J; Hernday N; Hokum M; Hu S; Knudten A; Levin N; Komorowski R; Martin F; Navarro R; Osslund T; Rogers G; Rogers N; Trail G; Egrie J
    Nat Biotechnol; 2003 Apr; 21(4):414-21. PubMed ID: 12612588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the quality and structural integrity of a complex glycoprotein mixture following extraction from the formulated biopharmaceutical drug product.
    Liu C; Dong S; Xu XJ; Yin Y; Shriver Z; Capila I; Myette J; Venkataraman G
    J Pharm Biomed Anal; 2011 Jan; 54(1):27-36. PubMed ID: 20800406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of lactation parameters on the N-glycosylation of recombinant human C1 inhibitor isolated from the milk of transgenic rabbits.
    Koles K; van Berkel PH; Mannesse ML; Zoetemelk R; Vliegenthart JF; Kamerling JP
    Glycobiology; 2004 Nov; 14(11):979-86. PubMed ID: 15253928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folding of glycoproteins: toward understanding the biophysics of the glycosylation code.
    Shental-Bechor D; Levy Y
    Curr Opin Struct Biol; 2009 Oct; 19(5):524-33. PubMed ID: 19647993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.